Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -63.4%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $648095 | $622672 | $13M | $100500 | $394000 | $999999 | $999999 | — | — | — | — |
| Enterprise Value | $-10629691 | $-7835435 | $12M | $-5406500 | $-1818000 | $-8291001 | $-6286001 | — | — | — | — |
| P/E Ratio → | -0.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 0.26 | 0.56 | 1.73 | 2.92 | — | — | — | — |
| P/B Ratio | 0.01 | 0.05 | 1.51 | 0.02 | 0.39 | 1.00 | 1.00 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -14.19 | -2.60 | -14.34 | -18.33 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -967.5% | -631.2% | -705.2% | -1669.1% | -1063.6% | -382.9% | -742.2% | -484.3% |
| Operating Margin | — | — | — | -2103.4% | -1277.8% | -1210.7% | -6717.2% | -1679.2% | -609.6% | -1190.7% | -729.6% |
| Net Profit Margin | — | — | — | -1858.0% | -1095.3% | -944.6% | -6469.1% | -1496.3% | -535.0% | -1183.5% | -465.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.4% | -63.4% | -88.1% | -180.6% | -112.5% | -63.6% | -168.9% | -55.3% | -40.2% | -29.1% | -13.3% |
| ROA | -37.9% | -37.9% | -45.2% | -88.1% | -83.0% | -48.0% | -109.0% | -39.3% | -29.8% | -22.1% | -10.2% |
| ROIC | -120.3% | -120.3% | -210.6% | -9934.7% | -634.5% | -1768.8% | -244.3% | -55.6% | -40.4% | -30.3% | -23.0% |
| ROCE | -75.9% | -75.9% | -125.0% | -186.4% | -121.5% | -78.2% | -143.7% | -52.4% | -40.2% | -26.7% | -18.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.09 | 0.10 | 0.20 | 0.07 | 0.04 | 0.31 | 0.07 | 0.19 | 0.05 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.11 | -1.18 | -0.70 | -0.89 | -1.08 | -0.25 | -0.06 | -0.19 | -0.34 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -120.77 | -120.77 | — | -181.56 | -159.15 | -137.77 | -689.29 | -111.61 | -20.12 | -117.99 | — |
Net cash position: cash ($9M) exceeds total debt ($60892)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.03 | 2.03 | 1.75 | 1.26 | 2.47 | 6.39 | 3.10 | 2.42 | 2.27 | 2.22 | 2.39 |
| Quick Ratio | 2.03 | 2.03 | 1.75 | 1.39 | 2.47 | 6.39 | 3.10 | 2.42 | 2.27 | 2.11 | 2.30 |
| Cash Ratio | 1.39 | 1.39 | 0.33 | 1.07 | 1.49 | 5.46 | 2.52 | 1.93 | 0.95 | 1.58 | 1.88 |
| Asset Turnover | — | — | — | 0.04 | 0.13 | 0.04 | 0.03 | 0.02 | 0.09 | 0.02 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 8.85 | 9.46 |
| Days Sales Outstanding | — | — | — | 674.44 | 171.80 | 20.84 | 101.09 | 980.73 | 16.76 | 823.74 | 393.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $54861 | $61952 | $30 | $1 | $1 | $1 | $0 | $0 | $0 | $0 |
Insufficient capital for trials
As reported in financial statements, BDRX trades at a price-to-book ratio of 0.01, a valuation level that suggests the market assigns negligible value to the company's intellectual property or future clinical prospects compared to the broader biotechnology sector's historical trading multiples.
The extreme discount to book value indicates that investors are heavily discounting the company's intangible assets, likely due to the high probability of further dilutive financing. This valuation profile implies that the market views the current pipeline as a high-risk option rather than a tangible asset base, warranting extreme caution regarding potential equity dilution.
Based on reported figures, the company's ROIC has fluctuated significantly, reaching -65.5% in 2025Q4, which highlights a persistent inability to generate positive returns on invested capital as the firm continues to prioritize R&D spending over immediate operational efficiency or profitability.
The volatility in ROIC, ranging from -2.1% to -196.4% over the last decade, reflects the erratic nature of clinical-stage biotech spending and the lack of a stable revenue base. This trend suggests that capital is being consumed at a rate that far outpaces the development of value-creating clinical milestones.
According to recent SEC filings, the current ratio of 2.03 in 2025Q4 provides a superficial appearance of liquidity, yet this metric is misleading given the company's lack of recurring revenue and the ongoing, non-discretionary cash burn required to sustain clinical trial operations.
While the current ratio appears adequate compared to historical lows, it does not account for the rapid depletion of cash reserves required for upcoming Phase II milestones. Investors should monitor the cash runway closely, as the current liquidity position may be insufficient to support the company's long-term development strategy without external capital intervention.
As noted in historical financial disclosures, the current ratio is frequently misapplied to BDRX, as it obscures the reality that the company's current assets are primarily cash reserves rather than working capital that can be replenished through normal business operations.
For a pre-revenue biotech, the current ratio serves as a countdown timer rather than a measure of operational health. Analysts should instead utilize a 'burn-adjusted' liquidity metric that compares cash reserves directly to quarterly R&D expenditures to better assess the true time remaining before the next capital raise.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BDRX stock.
Biodexa Pharmaceuticals Plc's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Biodexa Pharmaceuticals Plc's return on equity (ROE) is -63.4%. The historical average is -73.2%.
Based on historical data, Biodexa Pharmaceuticals Plc is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.